ReviewWorld journal of gastroenterology2014
Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04244877 (Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients), which is not on this map. Cited by 116 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients
Who cites it
116 citing papers in PubMed, 4 syntheses or guidelines pooled it, 226 citations in OpenAlex.
- Global distribution of Neorickettsia risticii, the causative agent of potomac horse fever: a systematic review.Veterinary research communications · 2026Pooled it
- Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2019Pooled it
- Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.Drug design, development and therapy · 2019Pooled it
- Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.Hepatology international · 2018Pooled it
- Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.Gut and liver · 2017Trial
- [Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Physiological and Anatomical Alterations in Children with Liver Cirrhosis.Pharmaceutical research · 2026Review
- Sodium-glucose cotransporter-2 inhibitors and the risk for liver abscess in patients with type 2 diabetes mellitus: a nationwide retrospective cohort study.Scientific reports · 2026Article
- Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.Journal of gastroenterology and hepatology · 2026Review
- Immunogenicity and plasmid delivery pathways of non-invasiveInfection and immunity · 2026Article
- Antibiotic exposure exacerbates acute-on-chronic liver failure via gut microbiota imbalance and secondary liver lesion.Journal of medical microbiology · 2026Article
- Gut-Liver Microbiome and Tumor Microenvironment in Metabolic Dysfunction-Associated Steatotic Liver Disease.Advances in experimental medicine and biology · 2026Review
- Geranylgeranoic acid, toll-like receptor 4, and pyroptosis-related signaling in hepatocellular carcinoma: a hypothesis-generating perspective.Oncology reviews · 2026Article
- Effects of tacrolimus treatment on the gut microbiota and metabolites in liver transplant recipients.PloS one · 2026Article
- Gluten's silent strike: Unmasking its impact on liver health.World journal of gastrointestinal pathophysiology · 2025Review
- Mucosal immunity and vaccination strategies: current insights and future perspectives.Molecular biomedicine · 2025Review
- A Systematic Review of the Effects of Probiotics and Synbiotics on Infection Incidence after Liver Transplant Surgery.Preventive nutrition and food science · 2025Article
- Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies.Biomedicines · 2025Review
- Liver-draining portal lymph node responds to enteric nematode infection by generating highly parasite-specific follicular T helper and B cell responses.Frontiers in immunology · 2025Article
- Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver disease is associated with qualitative and quantitative changes in the intestinal microbiota. In cirrhotic patients the alteration in gut microbiota is characterized by an overgrowth of potentially pathogenic bacteria (i.e., gram negative species) and a decrease in autochthonous familiae. Here we summarize the available literature on the risk of gut dysbiosis in liver cirrhosis and its clinical consequences. We therefore described the features of the complex interaction between gut microbiota and cirrhotic host, the so called "gut-liver axis", with a particular attention to the acquired risk of bacterial translocation, systemic inflammation and the relationship with systemic infections in the cirrhotic patient. Such knowledge might help to develop novel and innovative strategies for the prevention and therapy of gut dysbiosis and its complication in liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.